Amex Accepts Pro-Pharmaceuticals Compliance Plan
04 August 2008 - 1:00PM
Business Wire
Pro-Pharmaceuticals, Inc. (AMEX: PRW), a company developing
proprietary carbohydrate-based therapeutic compounds to treat
serious diseases such as cancer and fibrosis, today announced it
received notice from the American Stock Exchange ("Amex") staff
that the Amex has accepted the Company�s revised compliance plan
and will continue the Company�s listing to regain compliance with
the continued listing standards. The Company will be subject to
periodic review by Amex staff during the plan period. Failure to
make progress consistent with the plan, or to regain compliance
with the continued listing standards by the end of the plan period,
could result in the Company being de-listed from the Amex. In May
2008, Pro-Pharmaceuticals received notice from the Amex staff
indicating that the Company was below the Amex�s continued listing
standards due to losses in three of its last four years with
stockholders equity below $4 million as set forth in Section 1003
(a)(i) of the Amex Company Guide. As previously announced, the
Company was afforded an opportunity to submit a revised compliance
plan and presented it to the Amex in June and July. The Company
filed its initial compliance plan following an Amex notice in June
2007 that it did not meet a minimum stockholder equity requirement
of $2 million due to losses in two of its last three years. In
September 2007, the Amex accepted the Company�s initial plan and
granted an extension until October 13, 2008 to regain compliance
with the continued listing standards, subject to periodic review by
Amex during the extension period. About Pro-Pharmaceuticals, Inc. �
Advancing Drugs Through Glycoscience� Pro-Pharmaceuticals is a
clinical stage pharmaceutical company engaged in the discovery,
development and commercialization of carbohydrate-based, target
therapeutic compounds for advanced treatment of cancer, liver,
microbial and inflammatory diseases. The Company�s initial focus is
the development of carbohydrate polymers to treat cancer patients.
DAVANAT�, the Company�s lead product candidate, is a polysaccharide
polymer that is in Phase II trials for colorectal and biliary
cancer. The Company�s technology is also being used to develop new
chemical entities to treat liver and kidney fibrosis. The Company
is headquartered in Newton, Mass. Additional information is
available at www.pro-pharmaceuticals.com. FORWARD LOOKING
STATEMENTS: Any statements in this news release about future
expectations, plans and prospects for the Company, including
without limitation statements containing the words "believes,"
"anticipates," "plans," "expects," and similar expressions,
constitute forward-looking statements as defined in the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements are based on management's
current expectations and are subject to a number of factors and
uncertainties, which could cause actual results to differ
materially from those described in such statements. We caution
investors that actual results or business conditions may differ
materially from those projected or suggested in forward-looking
statements as a result of various factors including, but not
limited to, the following: uncertainties as to the utility and
market for our potential products; uncertainties associated with
pre-clinical and clinical trials of our product candidates. More
information about those risks and uncertainties is contained in the
Company's most recent quarterly or annual report and in the
Company's other reports filed with the Securities and Exchange
Commission. While the Company anticipates that subsequent events
may cause the Company's views to change, the Company disclaims any
obligation to update such forward-looking statements. DAVANAT and
Advancing Drugs Through Glycoscience are registered trademarks of
Pro-Pharmaceuticals.
Pro (AMEX:PRW)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Pro (AMEX:PRW)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Pro-Pharmaceuticals, (Amerikanische Börse): 0 Nachrichtenartikel
Weitere Pro-Pharmaceuticals, Inc. News-Artikel